Turkish Journal of Medical Sciences
Volume 49

Number 3

Article 3

1-1-2019

A pilot study on the beneficial effects of additional selenium
supplementation to methimazole for treating patients with
Graves' disease
BIN XU
DI WU
HONG YING
YING ZHANG

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
XU, BIN; WU, DI; YING, HONG; and ZHANG, YING (2019) "A pilot study on the beneficial effects of
additional selenium supplementation to methimazole for treating patients with Graves' disease," Turkish
Journal of Medical Sciences: Vol. 49: No. 3, Article 3. https://doi.org/10.3906/sag-1808-67
Available at: https://journals.tubitak.gov.tr/medical/vol49/iss3/3

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Medical Sciences

Turk J Med Sci
(2019) 49: 715-722
© TÜBİTAK
doi:10.3906/sag-1808-67

http://journals.tubitak.gov.tr/medical/

Research Article

A pilot study on the beneficial effects of additional selenium supplementation to
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Background/aim: The aim of this study was to assess the effect of a combination use of methimazole (MMI) and selenium (Se) in the
treatment of Graves’ disease (GD).
Materials and methods: A total of 103 newly diagnosed hyperthyroidism patients were randomized to MMI and MMI + Se combination
groups. After treatment for 6 months, the levels of triiodothyronine (FT3), free thyroxine (FT4), thyrotropin receptor antibody (TRAb),
thyroid peroxidase antibody (TPOAb), and thyroglobulin antibody (TGAb) were observed. An in vitro culture model of thyroid cells
was established and the protein expression and mRNA levels of TRAb, TPOAb, and TGAb were determined by western blot and RTPCR.
Results: A significant decrease in the levels of FT3, FT4, TRAb, TPOAb, and TGAb were observed in both groups along with a marked
increase in TSH levels. Furthermore, the in vitro experiments showed that the protein expression and mRNA levels of TRAb, TPOAb,
and TGAb decreased significantly. Also, compared to the MMI group, there was a greater improvement of these indices in the MMI +
Se group.
Conclusion: We suggest that the combined use of MMI and Se could improve the thyroid activity in patients, which may provide an
effective therapy for the treatment of GD in clinical settings.
Key words: Graves’ disease, methimazole, selenium, TRAb, TPOAb, TGAb

1. Introduction
Hyperthyroidism is an autoimmune disease that is
frequently seen in the endocrinology department. It
is caused by the excess release of thyroid hormone
through thyroid synthesis, resulting in hypermetabolism,
sympathetic nerve excitability, and finally palpitations,
sweating, increases in food intake and frequency of
stools, and weight loss (1). It is generally believed that
immune dysfunction is involved in the occurrence and
development of hyperthyroidism (2). Graves’ disease (GD)
is a common autoimmune disorder of the thyroid gland,
resulting in thyrotoxicosis secondary to thyroid receptor
autoantibodies, which accounts for 60% to 80% of the
global incidence of thyrotoxicosis (3,4). At present, the
treatment of hyperthyroidism mainly includes antithyroid
drugs (ATDs) (e.g., methimazole or propylthiouracil),
thyroidectomy, radioactive iodine (I131), and permanently
reduced thyroid function (5).

ATDs have been used as the principal treatment for
GD in both Europe and China. The treatment is usually
continued for 12 to 18 months, after which it is gradually
tapered off (ATD treatment withdrawal) (6). Methimazole
(MMI) is a common type of ATD (7–9). Its mode of action
is to inhibit thyroid peroxidase, which in turn inhibits
the coupling of tyrosine and iodide, and it effectively
reduces the biosynthesis of thyroid hormone (10). At the
same time, due to its less systemic adverse reaction to
hyperthyroidism, it has been widely used as a first-line
hyperthyroidism treatment in clinical settings (11,12).
GD is an autoimmune disease and is usually
accompanied by immunodeficiency (13). Thus, while
reducing thyroid hormones, improving the patient’s
immune status should also be considered. Selenium (Se)
is one of the essential trace elements in the human body
and is mainly concentrated in the thyroid gland. Se can
participate in the homeostasis of the thyroid hormone-
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dependent metabolic pathway, which plays an important
role in maintaining the integrity of the cell membrane,
iodine metabolism, and normal thyroid function. At the
same time, it can also eliminate free radicals and enhance
immune function systemically.
Although MMI and Se both have a significant effect
on the immune system as well as on the reduction of
autoantibodies, their combined clinical efficacy has
seldom been reported. We hypothesize that the addition of
Se supplementation to the usual treatment with MMI will
lead to a better clinical outcome and improve the quality
of life of patients with GD. Through clinical and in vitro
studies, we expect to provide a theoretical basis for the
clinical treatment of GD with a combination of MMI and
Se.
2. Materials and methods
2.1. Subjects
A total of 103 newly diagnosed patients with
hyperthyroidism were consecutively enrolled in the study
at our hospital from January 2016 through June 2017.
The inclusion criteria were as follows: 1) to have met
the diagnostic criteria for GD according to the Chinese
Diagnosis and Treatment of Thyroid Diseases guidelines;
2) no prior ATD use or contraindications for treatment
with ATDs before admission; 3) patients with no comorbid
diseases such as heart failure, kidney, or liver disease; 4)
a low level of thyroid-stimulating hormone (TSH) and
a high level of free thyroxine (FT4); 5) good compliance
with medical advice. The exclusion criteria were: 1) being
under 18 years of age; (2) severe heart or liver dysfunction;
(3) presence of other endocrine system and blood system
lesions; (4) pregnancy or lactation; (5) recent use of
immunosuppressive agents and ATDs. This study was
conducted with approval from the Ethics Committee of
Chongqing Emergency Medical Center. Written informed
consent was obtained from all participants.
2.2. Treatment
Patients were randomly divided into two groups, one group
receiving MMI and the other the MMI + Se combination.
Patients in the MMI group were given a placebo tablet
(twice a day) and a 30 mg MMI tablet (Merck KGaA,
Darmstadt, Germany) daily for 6 months. Patients in the
MMI + Se group received a 30 mg MMI tablet daily and
300 µg Se (twice a day) (Ling Tai Pharmaceutical Limited
by Share Ltd., Hei Longjiang, China) for 6 months. The
thyroid function of the patients was periodically reviewed
every month and the doses of MMI were gradually
reduced based on the recovery of thyroid function until
the minimal maintenance treatment dose was reached. At
the same time, the corresponding symptomatic treatment
was implemented according to the patient’s own condition.
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2.3. Observation indices
A total of 5 mL of venous blood was collected from each
patient before treatment, and this was repeated during
follow-up. The concentrations of free triiodothyronine
(FT3), free thyroxine (FT4), TSH, thyrotropin receptor
antibody (TRAb), thyroid peroxidase antibody (TPOAb),
and thyroglobulin antibody (TGAb) were measured
by chemiluminescent methods according to the
manufacturer’s instructions (Jiuding Co., Ltd., Tianjing,
China).
2.4. Thyroid tissue collection and cell cultures
The thyroid tissues of patients with hyperthyroidism
(n = 10, TP) and normal tissues around benign thyroid
adenoma (n = 10, NO) were obtained. None of the patients
had been treated previously with ATDs. The thyroid tissues
were minced and placed directly in plastic culture dishes,
and a 10-fold volume of sucrose solution (0.32 mol/L) was
added and then homogenized at 4 °C. After centrifugation,
the supernatant was taken and sucrose solution (2 mL, 0.80
mol/L) was added again. Centrifugation was performed
again and the precipitation was collected. An equivalent
volume of trypsin solution (0.25%, pH 8.0) was added
and the mixture was incubated at 37 °C with 5% CO2
for digestion. After the single-cell suspension was made,
cells were cultured in high-glucose Dulbecco’s modified
Eagle’s medium (DMEM) (HyClone, Logan, UT, USA)
supplemented with 10% (v/v) fetal bovine serum (FBS),
100 U/mL penicillin, and 100 mg/mL streptomycin and
were maintained in a humidified incubator with 5% CO2
at 37 °C.
2.5. Cell viability analysis
The
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-Htetrazolium bromide (MTT) method was performed to
evaluate the effect of MMI and Se on cell viability. Briefly,
thyroid tissue cells were seeded into 96-well culture plates
(5 × 105 cells/well) and treated with different concentrations
of MMI or Se (0–40 µM) for 24 h. Also, effect of time on
cell viability was observed (6–48 h). After treatment, the
cells were incubated with 5 mg/mL MTT solution for 4 h
at 37 °C. The medium was then removed and dissolved in
150 µL of dimethyl sulfoxide (DMSO) for another 10 min,
and analyzed spectrophotometrically. The absorbance of
the dye was measured at 570 nm using a microplate reader
(BioTek, Doraville, GA, USA).
2.6. Detection of cell apoptosis by flow cytometry
To evaluate the effect of MMI and Se on the apoptosis of
cultured thyroid tissue cells, an Annexin V-fluorescein
isothiocyanate (FITC) kit was used to detect apoptotic
cells. After treatment with MMI or Se, the cells were
harvested and washed with PBS and resuspended in
binding buffer. Then the cells were incubated with FITC
and propidium iodine (PI) for 15 min in the dark. Finally,
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cell apoptosis was detected with a flow cytometer (Becton
and Dickinson Influx, USA).
2.7. Detection of TRAb, TPOAb, and TGAb proteins
After treatment with MMI and/or Se for 24 h, the thyroid
cells were harvested and lysed in a RIPA and PMSF mixture
(RIPA:PMSF = 99:1). The total protein concentrations were
determined by using a bicinchoninic acid kit (Beyotime,
Jiangsu, China). Then equal amounts of proteins (50 µg/
lane) were separated by SDS-PAGE and transferred to
PVDF membranes. The membranes were incubated with
different primary antibodies, rabbit anti-TRAb (1:400,
Boster, Wuhan, China), rabbit anti-TPOAb (1:400, Boster),
or rabbit anti-TGAb (1:400, Boster), overnight at 4 °C. The
immunoblots were then incubated with antirabbit IgGhorseradish peroxidase (1:4000, Boster) as a secondary
antibody followed by ECL detection (Millipore, Billerica,
MA, USA).
2.8. Measurement of TRAb, TPOAb, and TGAb mRNA
levels
After treating with MMI and/or Se, the total RNA (1 µg)
of cells was isolated and reverse-transcribed into cDNA
according to the manufacturer’s instructions (TaKaRa,
Dalian, China). The PCR reaction was carried out using
the SYBR Premix Ex TaqTMII Kit (TaKaRa) according
to the manufacturer’s instructions. The primers of the
reaction system were designed and synthesized by Sangon
Biotech (Shanghai, China) as follows: TRAb forward
primer: 5′-GCAGCCAGGCACCAGAACATC-3′ and
reverse primer: 5′-TGCCAACAGCAGCCAAGAAGG-3′
(185
bp);
TGAb
forward
primer:
5′-TGCTGGCCTGGACCTTCCTTC-3′ and reverse
primer:
5′-CGGCGGCAGCTTGGAACATAG-3′

(177
bp);
TPOAb
forward
primer:
5′-CGCTCGCTGTGCTGTCTGTC-3′
and
reverse
primer: 5′-GTGGCGTACATGGCGGTGTC-3′ (163 bp).
All PCRs were performed in triplicate. GAPDH expression
was used for standardization, and the relative expression
analysis was assessed by the 2–ΔΔCt method.
2.9. Statistical analysis
All the data were presented as mean ± SD and analyzed
using SPSS 22.0 (IBM Corp, Armonk, NY, USA). Student’s
t-test and the chi-square test were employed for multiple
group comparisons. One-way ANOVA was performed
for repeated measures and the Student–Newman–Keuls
test was used for unequal sample numbers. P < 0.05 was
considered to be statistically significant.
3. Results
3.1. Comparison of thyroid function and MMI therapy
A total of 103 subjects were originally enrolled in this trial,
95 (92.23%) of whom completed the trial. No significant
differences were observed in age, sex, or levels of FT3, FT4,
TSH, TRAb, TPOAb, and TGAb between the two groups
before treatment (P > 0.05, Table). After 6 months of
treatment, the levels of FT3, FT4, TRAb, TPOAb, and TGAb
had significantly decreased in both groups, and TSH levels
had significantly increased (P < 0.05). Intriguingly, except
for TSH levels, the MMI + Se group showed substantially
more improvement in all of the measurements than the
MMI group (P < 0.05, Table).
3.2. Effects of MMI and Se on the cell viability of thyroid
cells
MTT was performed to evaluate the effect of MMI and/or
Se on cell viability. After treatment with MMI and/or Se

Table. The baseline parameters and clinical efficacy of the two groups (n = 95).

Groups

MMI
Before

MMI + Se
After

Before

F/c2

P

0.393

0.531

After

Sex
Male

19

14

Female

31

30

Age

40.20 ± 12.63

0.252

0.602

FT3

28.42 ± 14.76

13.39 ± 7.41*

27.93 ± 10.82

5.29 ± 1.02**

12.727

0.003

FT4

66.14 ± 26.52

16.59 ± 3.34**

70.97 ± 29.12

9.29 ± 4.27**

7.897

0.037

TSH

0.006 ± 0.001

2.11 ± 0.32**

0.004 ± 0.002

2.30 ± 0.54**

3.099

0.773

A-TG

772.69 ± 166.16

440.99 ± 104.27*

778.42 ± 199.90

366.37 ± 78.88*

57.752

<0.001

A-TPO

353.21 ± 36.71

128.28 ± 36.95

321.36 ± 30.02

95.22 ± 23.68*

0.848

<0.001

TRAb

21.01 ± 11.69

5.27 ± 3.46**

20.09 ± 12.51

3.33 ± 1.43*

3.953

0.004

38.89 ± 11.59

Data are represented as mean ± SD. *P < 0.05 and **P < 0.001 versus patients before treatment.
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for 24 h, the cell viability decreased with increasing drug
concentrations, especially when MMI reached 20 µM and
Se reached 40 µM (P < 0.05, Figures 1A and 1B). Moreover,
treatment for 6, 12, 24, and 48 h was also performed at
each of these concentrations, and there was no significant
change in cell viability (Figure 1C).
3.3. Effects of MMI and Se on apoptosis
To measure the rate of cell apoptosis and evaluate the
safety of MMI and Se, Annexin V/PI staining for flow
cytometric analysis was used. As depicted in Figure 2, our
data showed that no significant rate of apoptosis was found
after treatment with MMI, Se, or MMI + Se.
3.4. Effects of MMI and Se on the expression of TRAb,
TPOAb, and TGAb
Western blot and RT-PCR were used to detect the protein
expression or mRNA levels of TRAb, TPOAb, and TGAb
after the treatment of cells with MMI and/or Se for 24 h.
As shown in Figure 3, the protein expressions of TRAb,
TPOAb, and TGAb were significantly decreased when

compared with untreated cells. Moreover, the protein
expressions of these proteins were significantly more
decreased than those of the MMI treatment group (P <
0.05). The RT-PCR results were basically consistent with
the western blot results.
4. Discussion
Hyperthyroidism is a disease of the thyroid gland caused
by excessive secretion of thyroid hormones and is
classified as a multiple endocrine system disease (1,14).
Patients with hyperthyroidism are prone to relapse and
are greatly affected by genetic factors (15), making the
disease difficult to cure. Graves’ disease is a common
autoimmune disease of the thyroid gland and a leading
cause of hyperthyroidism worldwide (16). The detection
of TSH receptor autoantibodies can be used for a
diagnosis of GD and to explain the abnormal increase of
thyroid hormone concentration in blood (16). Through
treatment with MMI and/or Se, the levels of FT3 and FT4

Figure 1. The effects of MMI and Se on the cell viability of thyroid cells. Thyroid cells were treated with different concentrations of MMI
and/or Se and cell viability was observed by MTT. (A) NO group; (B) TP group; (C) cells treated with MMI and/or Se for 6, 12, 24, and
48 h. NO: Normal thyroid tissue; TP: hyperthyroidism tissue. The data are represented as mean ± SD. *P < 0.05 and **P < 0.001 versus
untreated group.
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Figure 2. The effects of MMI and Se on the level of apoptosis. Cells were treated with MMI (20 µM) and/or Se (40 µM) for 24 h. Images represent cell apoptosis and the percentage
of total apoptotic cells by Annexin V-FITC/PI staining assay. The data are represented as mean ± SD.
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Figure 3. Western blot and RT-PCR analysis of the effects of MMI and Se on the expression of TRAb, TPOAb, and TGAb. Cells were
treated with MMI (20 µM) and/or Se (40 µM) for 24 h. (A) Protein expressions of TRAb, TPOAb, and TGAb. (B) Representative images
of protein expressions of TRAb, TPOAb, and TGAb. (C) Representative images of mRNA expression of TRAb, TPOAb, and TGAb. The
data are represented as mean ± SD of three experiments. *P < 0.05 and **P < 0.001 versus untreated control group; #P < 0.05 versus
untreated control group.

were significantly reduced (P < 0.05). Also, the levels of
TSH increased remarkably. Together with these results, a
satisfactory clinical effect was obtained in this study.
MMI is one of the most common kinds of ATDs,
which can inhibit the synthesis of peroxidase and limit
the synthesis of TSH and FT3, thus improving the level
of thyroid hormone (10). Numerous studies have shown
that the concentration of drugs in the thyroid gland is
closely related to the daily dose of the drug (14,17,18).
Selenium is a necessary trace element of key importance
for homeostasis of the human system, especially for the
normal functioning of the immune system (19–21).
There are many hypotheses about the protective role of
selenium in thyroid diseases. At present, it is presumed
that Se supplementation can reduce the concentration
of antithyroid antigen antibodies, protect the thyroid
from oxidative stress, and optimize the synthesis and
transport of TH by inducing selenoprotein synthesis
(22). The immune system depends on adequate intake
of dietary selenium, and this nutrient plays its biological
role mainly by its incorporation into selenoproteins
(23). It has been assumed that a low level of Se can
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cause immune dysfunction, induce hypothyroidism, and
trigger insufficiency of the free radical scavenging system,
eventually leading to the death of thyroid immune cells
and the initiation of chronic inflammation (24).
MMI and Se have shown good results in treating
hyperthyroidism, and the mechanisms of treatment are
basically the same. Both drugs can inhibit the activity of
thyroid peroxidase and prevent iodine ions from oxidizing
to active iodine. By hindering the tyrosine condensation
reaction of iodization and inhibiting the synthesis of FT3
and FT4, they can both have antithyroid activity. After 6
months of treatment, our results showed that the levels
of FT3 and FT4 in the MMI + Se group were significantly
lower than those of the MMI group, and the level of TSH
was higher in the MMI + Se than in the MMI group (P
< 0.05), indicating that the effect of combination therapy
on hyperthyroidism is more prominent than that of MMI
alone.
The toxic effects of MMI and Se on cells were detected
by MTT and flow cytometry. The results showed that
when the concentrations of MMI and Se reached 20
µM and 40 µM, respectively, the cells began to exhibit
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apoptosis, indicating that the two drugs are safe to use.
At the same time, some studies have demonstrated the
benefits and safety of Se supplementation in the treatment
of hyperthyroidism (25–29). In a previous study, the levels
of FT3 and FT4 in patients with GD decreased rapidly after
treatment with MMI, and with the addition of Se, TSH
rose significantly. Our results are consistent with those of
Vrca et al. (30) to some extent.
TRAb is an antibody specific to humans and is the
main direct cause of hyperthyroidism. TRAb can be used
to predict the recurrence of GD. A decrease in TRAb
antibody titer can be seen as a sign of improvement during
the treatment of GD. At the same time, the lack of TRAb
can be used as an indicator to reflect the remission of GD
patients during the late treatment period (12,31). TPOAb
and TGAb are autoantibodies specific to thyroid disease,
and increasing antibody titers were observed in the early
stages of GD. The antibody titer gradually decreased with
remission of the disease (32,33). Previous studies showed

that Se therapy could reduce the level of TPOAb and
indicated that it has beneficial effects on immune activity
(5,34,35). Through in vivo and in vitro experiments, our
results showed that the levels of TRAb, TPOAb, and TGAb
were markedly lower in both serum and cells. Moreover,
the combination group had lower levels of antibodies than
the MMI group, showing that the combined use of MMI
and Se could significantly improve immune function in
the patients. Further studies will be focused on the clinical
effect of Se on GD.
In conclusion, clinical and in vitro experiments
were conducted to evaluate the therapeutic effect of the
combination of MMI and Se on hyperthyroidism, and our
results found that the group that received the combination
treatment had lower levels of FT3 and FT4 and lower
TRAb, TPOAb, and TGAb expressions than the MMI
group. Furthermore, higher TSH levels were observed
after treatment with MMI + Se. Thus, our results point to a
simple and safe strategy for treating hyperthyroidism.
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